NCT00082875终止2 期
A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the clinical efficacy of EMD 121974 at two different doses in patients with metastatic melanoma by determining the progression-free survival rate at 8 weeks.
SECONDARY OBJECTIVES:
I. To determine the response rate of EMD 121974 in patients with metastatic melanoma.
II. To determine the overall survival in patients who receive EMD 121974. III. To determine the safety and toxicity of EMD 121974 in patients with metastatic melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed stage IV or unresectable stage III metastatic melanoma of cutaneous, mucosal or unknown origin
- •Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 15 mm with conventional techniques or with spiral CT scan; in case of obviously visible cutaneous metastatic lesions, the margins of the lesions should be clearly defined and measured in at least one dimension as >= 10 mm
- •Patient may have received prior interferon therapy (only in an adjuvant setting for resected stage III melanoma) and/or up to 1 prior systemic treatment regimen (chemotherapy, biotherapy, or biochemotherapy) for stage IV disease; active vaccine therapy will not be considered as "prior systemic treatment"
- •Radiographic studies used to assess disease must have been performed within 21 days prior to registration; if a target lesion has been previously embolized, perfused or irradiated, there must be objective evidence of progression before start of therapy to be considered for response assessment
- •ECOG performance status ≤ 2 (or Karnofsky ≥ 60%)
- •Leukocytes >= 3,000/microL
- •Absolute neutrophil count >= 1,500/microL
- •Platelets >= 100,000/microL
- •Total bilirubin =< 1.5 X institutional upper limit of normal
- •ALT(SGPT) =< 2.5 X institutional upper limit of normal
- •Creatinine =< 1.5 X institutional upper limit of normal
- •Patient must have a hemoglobin >= 9 gm/dL (this may be achieved by transfusion if needed) obtained within 14 days prior to registration; in case that PRBC transfusion is needed to obtain a hemoglobin level of >= 9 gm/dL, the hemoglobin level should not be reduced more than 1 gm/dL for at least 1 week
- •The effects of EMD 121974 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because antiangiogenic agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Patients with metastatic melanoma of choroidal origin
- •Patients must not have received the following drugs prior to enrollment: endostatin, angiostatin, bevacizumab or any integrin-targeted drugs
- •Subjects who require concurrent treatment with a non-permitted medication (such as anticoagulant therapy other than for flushing of intravenous port device, or used for thrombosis prophylaxis)
- •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to grade 1 toxicity from adverse events due to agents administered more than 4 weeks earlier
- •Patients may not be receiving any other investigational agents
- •Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; however, the following is the exception; patients who have no radiographical evidence of recurrences in the brain for at least 3 months after the complete resection of the brain metastases or who have asymptomatic brain metastases stable for at least 3 months since the whole brain radiation therapy and/or stereotactic radiosurgery will be eligible for this study; patients must not require a steroid treatment for brain metastases
- •Subjects with a history of wound-healing disorders, advanced coronary disease (such as unstable angina pectoris or arrhythmia LOWN IV [defined as 2 or more consecutive ventricular premature complexes], cardiac or cardiovascular abnormalities NYHA III/IV), or with a recent history (within 6 months) of peptic ulcer disease
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Pregnant women are excluded from this study because EMD 121974 is an antiangiogenic agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with EMD 121974, breastfeeding should be discontinued if the mother is treated with EMD 121974; lactating women must not breastfeed
- •No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
研究组 & 干预措施
Arm I
Experimental
Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: *For the first course only, treatment is omitted on day 11
干预措施: pharmacological study (Other)
Arm II
Experimental
Patients receive cilengitide as in arm I at a higher dose.
干预措施: pharmacological study (Other)
Arm I
Experimental
Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: *For the first course only, treatment is omitted on day 11
干预措施: cilengitide (Drug)
Arm I
Experimental
Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: *For the first course only, treatment is omitted on day 11
干预措施: laboratory biomarker analysis (Other)
Arm II
Experimental
Patients receive cilengitide as in arm I at a higher dose.
干预措施: cilengitide (Drug)
Arm II
Experimental
Patients receive cilengitide as in arm I at a higher dose.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
PFS
时间窗: At 8 weeks
Each dose of EMD 121974 will be analyzed separately.
次要结局
- Response rate, calculated by the ratio of the number of (CR + PR) / total number of treated patients(Up to 4 years)
- PFS(Up to 4 years)
- Overall survival(Up to 4 years)
- Incidence of adverse events graded according to CTCAE version 3.0(Up to 4 years)
- Population Pharmacokinetics of EMD 121974, including Cmax, tmax, AUClast, t1/2, AUCinf, CL, Vz(Before and 2, 4, and 24 hours after dose of the first dose of courses 1 and 2 and before and 4 hours after dose of the third dose of courses 1 and 2)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Cilengitide in Treating Patients With Metastatic Prostate CancerRecurrent Prostate CancerStage IV Prostate CancerNCT00103337National Cancer Institute (NCI)106
终止
2 期
Cilengitide in Treating Patients With Acute Myeloid LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)NCT00089388National Cancer Institute (NCI)70
已完成
2 期
Cilengitide in Treating Patients With Prostate CancerRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerNCT00121238National Cancer Institute (NCI)16
已完成
1 期
Cilengitide in Treating Children With Refractory Primary Brain TumorsChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaNCT00063973National Cancer Institute (NCI)24
已完成
2 期
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard TherapyChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaRecurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood GlioblastomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaNCT00679354National Cancer Institute (NCI)30